CD274 and hepatocellular carcinoma: Atezolizumab is a fully humanized drug that targets the PD-1/PD-L1 pathway by blocking PD-L1 ligand and has been widely used in immunotherapies for patients with extensive-stage small cell lung cancer (ES-SCLC), unresectable hepatocellular carcinoma and breast cancer (47).